Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin mesylate in recurrent ovarian, fallopian tube, or peritoneal cancer
NCT00334893Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2006
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in ovarian epithelial cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Started Apr 2006; status: completed.
02
Drugs
eribulin
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00334893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00334893.